Despite the use of monoclonal antibodies (trastuzumab and pertuzumab) and HER2-targeting tyrosine kinase inhibitors (lapatinib, neratinib, and afatinib) as targeted therapies for HER2-positive bladder cancer, these single agents have failed to elicit satisfactory responses (35). Here, ERBB2 is linked to urinary bladder carcinoma.